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Abstract
Background: Infectious complications are frequent in severe acute pancreatitis (SAP) but multinational epi-
demiologic data are lacking. The aim of the study was to analyze the characteristics of the infectious com-
plications and antimicrobial use in this setting.
Methods: One-day point prevalence study of infection in critically ill patients (Extended Prevalence of In-
fection in the ICU-II study), performed in 1,265 ICUs in 75 countries.
Results: Of the 13,796 patients in the study, 159 were admitted with SAP. One-hundred sixteen (73%) had
infections: 31% intra-abdominal, 16% extra-abdominal, and 26% both. Gram-negative bacteria were more
prevalent than gram-positive organisms, anaerobes, or fungi. Therapeutically, penicillins and other beta-lactams
were used most frequently. Prophylactic antibiotics were administered to 24% of the patients with SAP.
Conclusions: Infections are frequent in patients admitted with SAP; most are intra-abdominal infections.
Microbiology is diverse with gram-negative micro-organisms most frequently isolated. Most patients admitted
to the ICU for SAP receive antibiotics at some point.
Severe acute pancreatitis (SAP) is often complicatedby pancreatic and extra-pancreatic infections [1,2]. Al-
though infection of pancreatic necrosis is an important
source of morbidity and mortality [3], other infections, such
as pneumonia and bacteremia, are frequent and may impact
outcomes [1]. Early diagnosis and prompt treatment with an-
tibiotics and appropriately-timed source control interventions
are the mainstays of therapy of infected necrosis [4,5]. Use of
prophylactic antibiotics to prevent infection was advocated in
the past, based largely on small, non-blinded studies. However,
recent randomized controlled trials could not demonstrate any
advantage of this tactic in patients with SAP [6,7]. But despite
recommendations against the routine use of prophylaxis in this
setting [8], many clinicians continue to administer antibiotics to
patients without culture-proved infection [9–11].
Antibiotics are best reserved for the treatment of estab-
lished infection [5], which can be diagnosed reliably using
fine-needle aspiration, guided either by computed tomogra-
phy or ultrasound [12]. However, data regarding current an-
tibiotic use in patients with SAP admitted either to the
intensive care unit (ICU) or to the regular ward are limited.
The Extended Prevalence of Infection in the ICU II (EPIC II)
was a large point-prevalence study of infections in the ICU.
The study showed that one-half of all ICU patients on the
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study day were infected and that 71% were treated with an-
tibiotics [13]. Intra-abdominal infections ranked second and
were present in 19.6% of the patients. The EPIC II study
database offers a unique opportunity to study the use of an-
tibiotics, either as prophylaxis or as therapy, in SAP patients
from multiple centers around the world. The objective of this
study was thus to analyze the characteristics of the infectious
complications and the use of antibiotics in EPIC II study
patients admitted to the ICU with SAP.
Patients and Methods
The EPIC II one-day point prevalence study of infection in
critically ill patients was performed on May 8, 2007. De-
mographic, physiologic, bacteriologic, and therapeutic data
were collected from 13,796 adult (age > 18 y) patients in
1,265 participating ICUs from 75 countries (see Appendix
online at www.liebertpub.com/sur) on the study day, as de-
scribed previously [13]. Local ethical committee approval at
each participating center was expedited or waived due to the
purely observational nature of the study. Infection was de-
fined according to the criteria of the International Sepsis
Forum and classified by the attending physician. Micro-
biologic analyses were performed locally. Participating ICUs
were asked to provide patient follow-up until hospital dis-
charge or for 60 d (until July 9, 2007), and ICU and hospital
outcomes were recorded. For the purposes of this study, we
selected the patients who were admitted to the ICU because
of SAP.
Statistical analysis
Statistical analyses were performed using PASW Statistics
18 for Windows (SPSS Inc, Chicago, USA). Data are pre-
sented as mean ( – standard deviation), or percentage as ap-
propriate, except for length of stay, which is reported as
median (interquartile range [IQR]). Difference testing be-
tween groups was performed using a Mann-Whitney test or
Fisher exact test as appropriate. All tests were two-tailed, and
a p value < 0.05 was considered statistically significant.
Results
Patient characteristics
One-hundred fifty-nine of the 13,796 patients (5%) were
admitted to the ICU because of SAP; 65% were male and the
mean age was 57– 15 years. The mean Simplified Acute
Physiology Score II was 34 – 14.2. Patients with SAP stayed
in the ICU for a median of 25 (10–53) days; ICU and hospital
mortality rates were 23% and 27%, respectively. The distri-
bution of patients according to their length of stay prior to the
study day is shown in Figure 1.
Patients with SAP were admitted to ICUs across all con-
tinents, with the highest proportion coming from Western
Europe (54%), followed by Latin America (19%), Eastern
Europe and Russia (9%), Asia (7), North America (6%), the
Pacific region (3%), and Africa (1%).
Infections
One hundred sixteen of the 159 patients with SAP (73%)
were diagnosed with an infection; 50 (31%) patients had intra-
abdominal infections, 25 (16%) had extra-abdominal infections,
and 41 (26%) had a combination of the two (Fig. 2). Extra-
abdominal infections included respiratory tract infections in 44
patients (28%), blood stream infections in 22 patients (14%),
both catheter-related infections in six (4%), genito-urinary tract
infections in six patients (4%), skin infections in five (3%), renal
infections in two patients (1%) and other infections in four
patients (3%).
In SAP patients with intra-abdominal infections, 66 dif-
ferent micro-organisms were isolated, with gram-negative
bacteria (n= 29) being the most prevalent (see Table 1); 32%
of the infections were polymicrobial. Escherichia coli and
Pseudomonas species were the most frequently isolated (in
10 patients each) bacteria. Candida albicans was detected in
eight patients.
FIG. 1. (A) Distribution of patients with severe acute
pancreatitis and (B) infection rate according to length of
stay in the intensive care unit prior to the study day.
FIG. 2. Distribution of sites of infection in patients ad-
mitted with severe acute pancreatitis. IAI= intra-abdominal
infection; EAI = extra-abdominal infection.
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The ICU length of stay was significantly longer in infected
versus non-infected SAP patients (median, 29 [11–63] days vs. 14
[6–30]; p< 0.001). Mortality rates in infected patients also
were higher in the ICU than in non-infected patients (ICU
mortality, 28% vs. 10%; p = 0.017; hospital mortality. 31%
vs. 17%, p = 0.084).
Antimicrobial use
A total of 133 of the 159 patients (84%) received antibiotics.
Penicillins and other beta-lactams were the antibiotics used
most frequently to treat established infections (Table 2).
Glycopeptides and anti-fungal agents were also used regularly.
Prophylactic antibiotics were administered to 38 of the 159
patients (24%), most often in patients who had been present on
the ICU for three weeks or less (Fig. 3); in this latter subgroup
of 72 patients, 22 (31%) were receiving prophylactic antibi-
otics (most frequently beta-lactams; Table 3). Twelve patients
(8%) received a prophylactic anti-fungal agent.
Among the antifungals administered for prophylaxis or
therapy, fluconazole was used most frequently: 34 patients
received fluconazole, six some formulation of amphotericin
B, four caspofungin, four voriconazole, and one patient re-
ceived an unspecified anti-fungal agent.
Discussion
In this cohort of patients admitted to the ICU with SAP,
infections were frequent and mortality was high. Although
intra-abdominal infections were most prevalent (occurring in
more than one-half the patients), extra-abdominal infections
also were common, with the lung being the most frequent
source of extra-abdominal infection. Most patients with SAP
were receiving antibiotics on the study day. Gram-negative
organisms were isolated most frequently from patients with
intra-abdominal infections, whereas yeasts were isolated less
frequently in these patients.
The high incidence of infectious complications is not
surprising because infection is one of the major complica-
tions in SAP and is strongly correlated with organ dysfunc-
tion. In a meta-analysis of 14 studies by Petrov et al. [3],
1,478 patients had acute pancreatitis; 314 (21%) of them
Table 1. Microbiology of Intra-Abdominal
Infections in Patients with Severe
Acute Pancreatitis
Gram-positive microorganisms (n = 25)
MSSA 1
MRSA 2
MSSE 3
MRSE 2
Streptococcus group D - MS 9
Streptococcus group D - MR 6
Streptococcus group A/B/C 1
Streptococcus (other) 1
Gram-negative micro organisms (n= 29)
Escherichia coli 10
Enterobacter species 3
Klebsiella species 6
Proteus species 3
Salmonella species 1
Pseudomonas species 10
Stenotrophomonas maltophilia 1
Acinetobacter species 4
Other 1
ESBL-producing gram-negative organisms 0
Anaerobes (n = 3)
Clostridium species 3
Fungi (n = 9)
Candida albicans 8
Candida non-albicans 1
Other (n = 1)
MSSA=methillicin-sensitive Staphylococcus aureus; MRSA=
methicillin-resistant Staphylococcus aureus; MSSE=Staphylococcus
epidermidis; MRSE=methicillin-resistant Staphylococcus epidermidis;
MS=methillicin-sensitive; MR=methicillin-resistant; ESBL=
extended-spectrum beta-lactamase.
Table 2. Antibiotics Administered for Established
Infections in 116 Patients Admitted
for Severe Acute Pancreatitis
Carbapenem 49
Anti-fungal 40
Glycopeptide 30
Penicillin 29
Fluoroquinolone 19
Cephalosporin 15
Aminoglycoside 13
Other 38
FIG. 3. Proportion of patients receiving prophylactic or
therapeutic antibiotics on the study day according to the
length of stay in the intensive care unit prior to the study
day.
Table 3. Prophylactic Antibiotics administered
to Patients with Severe Acute Pancreatitis
Carbapenem 17
Antifungal 12
Aminoglycoside 5
Cephalosporin 4
Fluoroquinolone 3
Penicillin 3
Other AB 11
AB= antibiotics.
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developed infected pancreatic necrosis, with an incidence in
the individual reports ranging from 4% to 63%. In the group
of 713 patients considered for the PROPATRIA study, of
whom only 154 had documented pancreatic necrosis, Bes-
selink et al. reported infected pancreatic necrosis in 98 pa-
tients [1], yielding an incidence of 63.3%. In a multi-center
audit from Italy, 56 of 161 patients with demonstrated pan-
creatic necrosis developed infection [10]. It was not clear
how many patients were admitted to the ICU, so it is difficult
to compare that study to the present analysis.
The denominator is important when comparing the inci-
dence of infection in different studies. Most studies in pa-
tients with SAP have included patients admitted to the ICU,
as well as to general wards or high-dependency units, so
differences in patient populations are likely to explain the
observed variability in the incidence of infections in these
patients. From the Simplified Acute Physiology Score II
score, it can be assumed that the present study population was
sicker, compared with that of most observational reports.
Moreover, the design of the study (a point-prevalence study)
may also affect the results. Patients with infected pancreatic
necrosis have a protracted ICU course, which explains the
long length of stay of the patients in this study, and increases
the probability that infection of pancreatic necrosis was
present. On the other hand, patients who have been admitted
for one week or less (the largest group in the present study)
are less likely to have developed infection; the median delay
to infected pancreatic necrosis in the study by Besselink et al.
was 26 d [1].
Although mortality was high overall, the separate effects
of pancreatic or extra-pancreatic infections on outcome
cannot be estimated from this study, as these data were not
collected in the EPIC-II study. Petrov et al. reviewed the
impact of infection and multiple organ dysfunction syndrome
in patients with acute pancreatitis and reported that these two
factors were equally important but when both were present,
mortality rates were doubled [3]. Others have found in-
creased mortality rates in patients with pneumonia or infected
pancreatic necrosis and bacteremia [1].
As in other reports, gram-negative bacteria were most
prevalent, with Escherichia coli the most frequently isolated
microorganism. Notably, problematic organisms, such as
Pseudomonas and Acinetobacter species, were common
among the gram-negative organisms, but the same effect was
not found among the gram-positive microorganisms. Re-
markably, none of the reported microorganisms was ex-
tended-spectrum beta-lactamase producing.
Fungal infections are equally feared in this setting, yet
fungi were less predominant in this series compared to pre-
vious reports [14,15]. The frequent use of anti-fungal agents
in our study may explain these findings. Anti-fungals have
been recommended often based on earlier studies that high-
lighted the importance of yeasts [16–18] and suggested an
advantage of prophylactic administration of anti-fungal
agents [19].
The use of antibiotics as prophylaxis was considerable in
this study. Although the use of prophylactic antibiotics to
prevent infected pancreatic necrosis was once adopted ea-
gerly based on a number of small, uncontrolled studies [5],
subsequent randomized controlled trials could not find any
advantage of this strategy [6,7]. This observation was upheld
in the most recent meta-analyses [20,21] and the approach is
no longer recommended by scientific societies [8]. Our study
shows that in clinical practice, these recommendations are
often disregarded. A recent Italian survey similarly reported
that antibiotic prophylaxis is widely used in clinical practice,
with 25% of patients with mild or moderate SAP receiving
antibiotic prophylaxis [10]. In addition, data from a large
study on probiotics from The Netherlands (the PROPATRIA
study) also showed that 20–25% of patients received antibi-
otics without proved infection [11]. However, patients in
these studies were recruited before the most recent evidence
was published, and therefore likely reflect the earlier treat-
ment policy. The same comment may apply to the current
analysis, although the 2004 Consensus Conference on the
management of SAP already advised against the use of pro-
phylactic antibiotics to prevent pancreatic infection [8]. The
different classes of antibiotics used for prophylaxis reflect
the heterogeneity of the initial studies on which antibiotic
prophylaxis for acute pancreatitis patients was based. Ther-
apeutic antibiotic choices also were diverse; the unpredict-
able microbiology and variable antibiotic susceptibility are
probably the major explanations for this finding.
This study provides a real-life snapshot of infectious com-
plications and antibiotic use in unselected patients admitted
with SAP across different countries and continents. This co-
hort is unique but the study also has a number of limitations. As
stated earlier, the population may be skewed towards more
patients with prolonged lengths of stay and therefore may not
accurately reflect the incidence of infection all SAP patients.
The point prevalence nature of the study did not allow us to
determine whether the prophylaxis was associated with dif-
ferent rates or patterns of infection. Furthermore, details re-
garding the etiology or severity of the pancreatitis were not
available and microbiology was performed locally, with po-
tential differences in methodology and reporting.
In conclusion, our results show that SAP is a relatively
uncommon indication for ICU admission but is associated
with high ICU mortality rates. Infections appear to be a major
problem in this population of patients and, although intra-
abdominal infections are most frequent, a substantial
proportion of patients are treated for infection at an extra-
abdominal site. Microbiology is diverse with gram-negative
infections being most frequent, and fungal infections rela-
tively uncommon. Most patients admitted to the ICU for
SAP receive antibiotics. Antibiotic prophylaxis, although
not supported by scientific evidence, is still practiced widely.
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